VYNE director Rex Bright dies; board appoints LePore, Sandoval; MST sale yields $20M upfront

VYNE Therapeutics Inc.

Director Rex Bright passed away on Jan 11, 2022; he chaired Compensation Committee and served on Audit Committee.
Board appointed Patrick LePore to Audit Committee and Elisabeth Sandoval as chair of Compensation Committee on Jan 14, 2022.
MST franchise sold to Journey Medical for $20M upfront, $5M in 1 year, plus up to $450M in milestone payments.
Pro forma balance sheet shows cash of $67.9M after sale; discontinued operations eliminate product sales revenues.
Pro forma net loss from continuing ops for nine months ended Sep 30, 2021 was $37.1M, down from $61.8M historical.

item 9.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rex Bright

Director

VYNE · VYNE Therapeutics Inc.

Effective: 2022-01-11
Filed: January 14, 2022, 6:59 PM ET

The Company deeply regrets to announce that Mr. Rex Bright passed away on January 11, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Rex Bright departed as Director at VYNE Therapeutics Inc..

Action: passed away
Role: Director

Exact text from the filing

The Company deeply regrets to announce that Mr. Rex Bright passed away on January 11, 2022.

View on SEC.gov

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-004497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.